Aug. 23, 2023, FDA grants priority review for XTANDI(enzalutamide) in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
XTANDI (enzalutamide) is an androgen receptor signaling inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.XTANDI is currently approved for one or more of these indications in more than 100 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.
Поиск 
+86 21 5895 0110 
